Pharmacokinetics and Safety of BI 695501 in Healthy Subjects: a Randomized, Open-label, Single Dose, Parallel Arm, Active Comparator Clinical Phase I Study.
Phase of Trial: Phase I
Latest Information Update: 14 Nov 2012
At a glance
- Drugs Adalimumab (Primary)
- Indications Inflammatory bowel diseases; Psoriasis; Rheumatoid arthritis
- Focus Pharmacokinetics
- 25 Jul 2012 Actual end date (Jul 2012) added as reported by ClinicalTrials.gov.
- 25 Jul 2012 Actual patients number (193) added as reported by ClinicalTrials.gov.
- 01 Jul 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.